TABLE 1.
Baseline characteristics of breast cancer survivors in a 2 × 2 factorial randomized controlled trial of metformin and weight loss (n = 333)a
| Age, mean years (SD) | 62.6 (6.9) |
| Education, N (%) | |
| College graduate or graduate school | 171 (51.3%) |
| Some college | 132 (39.6%) |
| High school or less | 30 (9.0%) |
| Time since diagnosis, mean years (SD) | 2.7 (2.0) |
| BMI, kg/m2 (SD) | 31.1 (5.0) |
| Race, N (%) | |
| White | 278 (83.5%) |
| Black or African-American | 12 (3.6%) |
| sian | 6 (1.8%) |
| Mixed or other race | 37 (11.1%) |
| Ethnicity, N (%) | |
| Non-Hispanic | 295 (88.6%) |
| Hispanic | 38 (11.4%) |
| Cancer stage, N (%) | |
| Stage I | 161 (48.4%) |
| Stage II | 116 (34.8%) |
| Stage III | 56 (16.8%) |
| Receptor status, N (%) | |
| ER+ or PR+ HER2- | 240 (72.1%) |
| HER2+ | 51 (15.3%) |
| Triple negative (ER-, PR-, and HER2-) | 30 (9.0%) |
| Missing data | 12 (3.6%) |
| Received chemotherapy, N (%) | 177 (53.2%) |
| Received hormone therapy, N (%) | 229 (68.8%) |
| Neurocognitive score, mean (SD) | |
| Attention | 102.9 (8.84) |
| Executive function | 102.9 (10.96) |
| Memory | 105.1 (8.97) |
| Verbal function | 101.1 (17.20) |
| Visual spatial | 110.3 (13.54) |
Abbreviations: BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; SD, standard deviation.
a
There were no significant differences across the study arms.